disease. Clin Genet 1989; 36:431.731 731. Moore RC, Xiang F, Monaghan J, et al. Huntington disease phenocopy is a familial prion disease. Am J Hum Genet 2001; 69:1385.
732 732. Evers‐Kiebooms G, Swerts A, Cassimann JJ, et al. The motivation of at‐risk individuals and their partners in deciding for or against predictive testing for Huntington's disease. Clin Genet 1989; 35:29.
733 733. Sorenson SA, Fenger K. Suicide in patients with Huntington's disease and their sibs. Am J Hum Genet 1991; 49:316.
734 734. Schoenfeld M, Myers RH, Cupples LA, et al. Increased rate of suicide among patients with Huntington's disease. J Neurol Neurosurg Psychiatry 1984; 47:1283.
735 735. Almqvist EW, Bloch M, Brinkman R, et al., on behalf of an International Huntington Disease Collaborative Group. A worldwide assessment of the frequency of suicide, suicide attempts or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet 1999; 64:1293.
736 736. van Duijn E, Kingma EM, van der Mast RC. Psychopathology in verified Huntington's disease gene carriers. J Neuropsychiatry Clin Neurosci 2007; 19:441.
737 737. Kachian ZR, Cohen‐Zimerman S, Bega D, et al. Suicidal ideation and behavior in Huntington's disease: systematic review and recommendations. J Affect Disord 2019; 250:319.
738 738. McGarry A, McDermott MP, Kieburtz K, et al. Risk factors for suicidality in Huntington disease. Neurology 2019; 92:e1643.
739 739. Wesson M, Boileau NR, Perlmutter JS, et al. Suicidal ideation assessment in individuals with premanifest and manifest Huntington disease. J Huntingtons Dis 2018; 7:239.
740 740. Markel DS, Young AB, Penney JB. At‐risk persons' attitudes toward presymptomatic and prenatal testing of Huntington's disease in Michigan. Am J Med Genet 1987; 26:295.
741 741. Lamport AN. Presymptomatic testing for Huntington's chorea: ethical and legal issues. Am J Med Genet 1987; 26:307.
742 742. Taylor CA, Myers RH. Long‐term impact of Huntington disease linkage testing. Am J Med Genet 1997: 70:365.
743 743. Hayden MR. Predictive testing for Huntington disease: are we ready for widespread community implementation? Am J Med Genet 1991; 40:515.
744 744. Nance MA, Leroy BS, Orr HT, et al. Protocol for genetic testing in Huntington disease: three years of experience in Minnesota. Am J Med Genet 1991; 40:518.
745 745. Decruyenaere M, Evers‐Kiebooms G, Cloostermans T, et al. Psychological distress in the 5‐year period after predictive testing for Huntington's disease. Eur J Hum Genet 2003; 11:30.
746 746. Winnberg E, Winnberg U, Pohlkamp L, et al. What to do with a second chance in life? Long‐term experiences of non‐carriers of Huntington's disease. J Genet Couns 2018; 27:1438.
747 747. Gusella JF, McNeil S, Persichetti F, et al. Huntington's disease. Cold Spring Harb Symp Quant Biol 1996; 61:615.
748 748. Kremer B, Goldberg P, Andrew SE. A worldwide study of the Huntington's disease mutation: the sensitivity and specificity of measuring CAG repeats. N Engl J Med 1994; 330:1401.
749 749. Alonso ME, Yescas P, Rasmussen A, et al. Homozygosity in Huntington's disease: new ethical dilemma caused by molecular diagnosis. Clin Genet 2002; 61:437.
750 750. Evans DGR, Maher EF, Macleod R, et al. Uptake of genetic testing for cancer predisposition. J Med Genet 1997; 34:746.
751 751. Veldhuisen B, Saris JJ, deHaij S, et al. A spectrum of mutations in the second gene for autosomal dominant polycystic kidney disease (PKD2). Am J Hum Genet 1997; 61:547.
752 752. Deltas CC, Christodoulou K, Tjakouri C, et al. Presymptomatic molecular diagnosis of autosomal dominant polycystic kidney disease using PKD1‐ and PKD2‐linked markers in Cypriot families. Clin Genet 1996; 50:10.
753 753. Pirson Y, Chaveau D. Intracranial aneurysms in autosomal dominant polycystic kidney disease. In: Watson ML, Torres VE, eds. Polycystic kidney disease. Oxford: Oxford University Press, 1996:530.
754 754. Liu D, Wang CJ, Judge DP, et al. A Pkd1‐Fbn1 genetic interaction implicates TGF‐β signaling in the pathogenesis of vascular complications in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2014; 25:81.
755 755. Sujansky E, Kreutzer SB, Johnson AM, et al. Attitudes of at‐risk and affected individuals regarding presymptomatic testing for autosomal dominant polycystic kidney disease. Am J Med Genet 1990; 35:510.
756 756. Hannig VL, Hopkins JR, Johnson HK, et al. Presymptomatic testing for adult onset polycystic kidney disease in at‐risk kidney transplant donors. Am J Med Genet 1991; 40:425.
757 757. Oyazato Y, Iijima K, Emi M, et al. Molecular analysis of TSC2/PKD1 contiguous gene deletion syndrome. Kobe J Med Sci 2011; 57:E1.
758 758. Giardiello FM, Brensinger JD, Petersen GM, et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 1997; 336:823.
759 759. Hogan J, Turner A, Tucker K, et al. Unintended diagnosis of Von Hippel‐Lindau syndrome using Array Comparative Genomic Hybridization (CGH): counseling challenges arising from unexpected information. J Genet Couns 2013; 22:22.
760 760. Telander RL, Zimmerman D, Sizemore GW, et al. Medullary carcinoma in children: results of early detection and surgery. Arch Surg 1989; 124:841.
761 761. Ross LF. Predictive genetic testing for conditions that present in childhood. Kennedy Inst Ethics J 2002; 12:225.
762 762. Wertz DC, Fanos JH, Reilly PR. Genetic testing for children and adolescents: who decides? JAMA 1994; 272:875.
763 763. Lancaster JM, Wiserman RW, Berchuk A. An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast‐ovarian cancer susceptibility gene. Obstet Gynecol 1996; 87:306.
764 764. DudokdeWit AC, Tibben A, Frets PG, et al. BRCA1 in the family: a case description of the psychological implications. Am J Med Genet 1997; 71:63.
765 765. Julian‐Reynier C, Eisinger F, Vennin P, et al. Attitudes towards cancer predictive testing and transmission of information to the family. J Med Genet 1996; 33:731.
766 766. Lancaster JM, Wiseman RW, Berchuck A. An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast‐ovarian cancer susceptibility gene. Obstet Gynecol 1996; 87:306.
767 767. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72:1117.
768 768. National Comprehensive Cancer Network. Practice guidelines in oncology. Genetic/familial high‐risk assessment: breast and ovarian. Version 1. Fort Washington, PA: National Comprehensive Cancer Network, 2008.
769 769. Burke W, Daly M, Garber J, et al. Recommendations for follow‐up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997; 277:997.
770 770. King M‐C, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003: 302;643.
771 771. Laken SJ, Petersen GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable
